CN105209909B - 与肾功能相关的生物标记及其使用方法 - Google Patents

与肾功能相关的生物标记及其使用方法 Download PDF

Info

Publication number
CN105209909B
CN105209909B CN201480027332.7A CN201480027332A CN105209909B CN 105209909 B CN105209909 B CN 105209909B CN 201480027332 A CN201480027332 A CN 201480027332A CN 105209909 B CN105209909 B CN 105209909B
Authority
CN
China
Prior art keywords
renal function
subject
purposes
level
ckd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480027332.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN105209909A (zh
Inventor
R·皮里崇
J·E·寇博
M·V·布朗
A·肯尼迪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Metabolon Inc
Original Assignee
Metabolon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabolon Inc filed Critical Metabolon Inc
Priority to CN201910484069.9A priority Critical patent/CN110196335A/zh
Publication of CN105209909A publication Critical patent/CN105209909A/zh
Application granted granted Critical
Publication of CN105209909B publication Critical patent/CN105209909B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/64—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving ketones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/70—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving creatine or creatinine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biophysics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201480027332.7A 2013-05-14 2014-05-13 与肾功能相关的生物标记及其使用方法 Active CN105209909B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910484069.9A CN110196335A (zh) 2013-05-14 2014-05-13 与肾功能相关的生物标记及其使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361822965P 2013-05-14 2013-05-14
US61/822,965 2013-05-14
PCT/US2014/037762 WO2014186311A1 (en) 2013-05-14 2014-05-13 Biomarkers related to kidney function and methods using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201910484069.9A Division CN110196335A (zh) 2013-05-14 2014-05-13 与肾功能相关的生物标记及其使用方法

Publications (2)

Publication Number Publication Date
CN105209909A CN105209909A (zh) 2015-12-30
CN105209909B true CN105209909B (zh) 2019-06-07

Family

ID=51898805

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201480027332.7A Active CN105209909B (zh) 2013-05-14 2014-05-13 与肾功能相关的生物标记及其使用方法
CN201910484069.9A Pending CN110196335A (zh) 2013-05-14 2014-05-13 与肾功能相关的生物标记及其使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201910484069.9A Pending CN110196335A (zh) 2013-05-14 2014-05-13 与肾功能相关的生物标记及其使用方法

Country Status (10)

Country Link
US (2) US10539575B2 (enExample)
EP (3) EP2997366B1 (enExample)
JP (1) JP6595984B2 (enExample)
CN (2) CN105209909B (enExample)
AU (1) AU2014265669B2 (enExample)
BR (1) BR112015028253A2 (enExample)
CA (2) CA3184836A1 (enExample)
ES (2) ES2702123T3 (enExample)
MX (2) MX391220B (enExample)
WO (1) WO2014186311A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3184836A1 (en) * 2013-05-14 2014-11-20 Metabolon, Inc. Biomarkers related to kidney function and methods using the same
CN111239415B (zh) 2013-10-17 2024-03-26 综合医院公司 鉴定响应于用于自身免疫性疾病的治疗的受试者的方法以及用于治疗该疾病的组合物
US10254272B2 (en) * 2015-01-09 2019-04-09 Global Genomics Group, LLC Blood based biomarkers for diagnosing atherosclerotic coronary artery disease
WO2016115496A1 (en) * 2015-01-15 2016-07-21 Joslin Diabetes Center Metabolite biomarkers predictive of renal disease in diabetic patients
EP3355914B1 (en) 2015-09-29 2024-03-06 The General Hospital Corporation A composition comprising bcg for reducing cholesterol.
US20170234874A1 (en) * 2015-10-07 2017-08-17 Clearbridge Biophotonics Pte Ltd. Integrated visual morphology and cell protein expression using resonance-light scattering
US12057228B1 (en) 2015-12-30 2024-08-06 Cerner Innovation, Inc. Predicting newly incident chronic kidney disease
AU2017301949B2 (en) * 2016-07-28 2021-09-23 Metabolon, Inc. Compounds, reagents, and uses thereof
EP3552022B1 (en) * 2016-11-25 2021-06-09 Implexion AB Metabolic disorders
WO2018118630A1 (en) 2016-12-19 2018-06-28 Metabolon, Inc. Mass spectrometry assay method for detection and quantitation of kidney function metabolites
CN108956790A (zh) * 2017-05-18 2018-12-07 中国人民解放军第二军医大学第二附属医院 一组氨基酸标志物在急性肾损伤诊断试剂盒中的应用
CN107132266A (zh) * 2017-06-21 2017-09-05 佛山科学技术学院 一种基于随机森林的水质分类方法及系统
EP3665705B1 (en) 2017-08-08 2024-12-18 Fresenius Medical Care Holdings, Inc. Systems and methods for treating and estimating progression of chronic kidney disease
CN107326093B (zh) * 2017-09-04 2020-01-21 东南大学 基于Taqman探针的慢性肾脏病相关基因检测荧光定量PCR一步法试剂盒及其应用
CA3077029A1 (en) * 2017-09-28 2019-04-04 Metabolon, Inc. Compounds, reagents, and uses thereof
CA3089817A1 (en) * 2018-01-19 2019-07-25 Mars, Incorporated Biomarkers and classification algorithms for chronic kidney disease in cats
US20210327589A1 (en) * 2018-07-14 2021-10-21 Mars, Incorporated Biomarkers and test models for chronic kidney disease
WO2020171158A1 (ja) * 2019-02-20 2020-08-27 株式会社パートナーファーム 固相反応チップ及びこれを用いた測定方法
WO2021018774A1 (en) * 2019-07-26 2021-02-04 Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) Ergothioneine, s-methyl-ergothioneine, and uses thereof
CN112305089B (zh) * 2019-07-26 2022-04-29 长沙都正生物科技股份有限公司 一种慢性肾病诊断生物标记物及其应用
CN111487338B (zh) * 2020-04-16 2022-06-10 中南大学湘雅二医院 一种与肾功能相关的无创生物标记物及其应用
WO2021232211A1 (zh) * 2020-05-19 2021-11-25 深圳市中医院 诊断肾病的标志物以及诊断方法
KR102697110B1 (ko) 2020-12-07 2024-08-22 킴벌리-클라크 월드와이드, 인크. 대사산물을 검출하기 위한 방법 및 소비자 제품
CN114910587B (zh) * 2022-05-12 2024-03-19 军科正源(上海)生物医药科技有限公司 一种尿液检测用高效液相-串联质谱分析方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712084A (en) * 1995-09-08 1998-01-27 Research Corporation Technologies, Inc. Donor kidney viability test for improved preservation
CN101377492A (zh) * 2007-08-29 2009-03-04 北京九强生物技术有限公司 胱抑素c测定试剂盒
WO2013048344A1 (en) * 2011-09-29 2013-04-04 National University Of Singapore Urinary metabolomic markers for renal insufficiency

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02196787A (ja) 1989-01-25 1990-08-03 Otsuka Pharmaceut Co Ltd シュードウリジン誘導体
JPH0661278B2 (ja) 1990-09-18 1994-08-17 旭化成工業株式会社 ミオイノシトールの高感度定量法および定量用組成物
EP2324354B1 (en) * 2008-08-29 2014-07-16 Astute Medical, Inc. Methods for prognosis of acute renal failure
US9421330B2 (en) * 2008-11-03 2016-08-23 Bayer Healthcare Llc Mitigation of contrast-induced nephropathy
CN104034901A (zh) * 2008-11-22 2014-09-10 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
WO2010124269A1 (en) 2009-04-24 2010-10-28 National Center For Genome Resources Methods for diagnosis of sepsis and risk of death
JP5197846B2 (ja) * 2009-04-30 2013-05-15 紀陽 田仲 腎疾患重篤度を判定する方法又は装置若しくはその作動方法
US8637482B2 (en) * 2009-06-08 2014-01-28 Quark Pharmaceuticals, Inc. Methods for treating chronic kidney disease
JP5757626B2 (ja) 2009-09-04 2015-07-29 国立大学法人東北大学 ヒトにおける新たな腎疾患マーカー物質
KR20120123056A (ko) 2009-12-20 2012-11-07 아스튜트 메디컬 인코포레이티드 신손상 및 신부전을 진단 및 예측하는 방법 및 조성물
WO2011146683A1 (en) * 2010-05-19 2011-11-24 Metabolon, Inc. Methods and reagents for metabolomics and histology in a biological sample and a kit for the same
CA2802273A1 (en) 2010-08-06 2012-02-09 Pronota N.V. Perlecan as a biomarker for renal dysfunction
JP5916058B2 (ja) 2011-08-26 2016-05-11 国立大学法人東北大学 細胞ストレス状態のバイオマーカー
KR20140074293A (ko) 2011-09-14 2014-06-17 바스프 에스이 신장 독성을 평가하기 위한 수단 및 방법
CA3184836A1 (en) * 2013-05-14 2014-11-20 Metabolon, Inc. Biomarkers related to kidney function and methods using the same
AU2017301949B2 (en) * 2016-07-28 2021-09-23 Metabolon, Inc. Compounds, reagents, and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712084A (en) * 1995-09-08 1998-01-27 Research Corporation Technologies, Inc. Donor kidney viability test for improved preservation
CN101377492A (zh) * 2007-08-29 2009-03-04 北京九强生物技术有限公司 胱抑素c测定试剂盒
WO2013048344A1 (en) * 2011-09-29 2013-04-04 National University Of Singapore Urinary metabolomic markers for renal insufficiency

Also Published As

Publication number Publication date
HK1218331A1 (zh) 2017-02-10
AU2014265669B2 (en) 2020-05-14
EP3546940A1 (en) 2019-10-02
HK1222905A1 (en) 2017-07-14
EP3546940B1 (en) 2021-02-17
MX365061B (es) 2019-05-22
WO2014186311A1 (en) 2014-11-20
CN110196335A (zh) 2019-09-03
US20200103417A1 (en) 2020-04-02
US20160116486A1 (en) 2016-04-28
MX2015015561A (es) 2016-02-05
EP2997366A4 (en) 2017-04-12
BR112015028253A2 (pt) 2017-07-25
CN105209909A (zh) 2015-12-30
AU2014265669A1 (en) 2015-12-24
CA2911204C (en) 2023-03-28
MX391220B (es) 2025-03-21
US10539575B2 (en) 2020-01-21
JP6595984B2 (ja) 2019-10-23
JP2016520192A (ja) 2016-07-11
ES2702123T3 (es) 2019-02-27
EP2997366A1 (en) 2016-03-23
EP3410115A1 (en) 2018-12-05
CA3184836A1 (en) 2014-11-20
CA2911204A1 (en) 2014-11-20
MX2019005748A (es) 2019-08-12
ES2871823T3 (es) 2021-11-02
EP2997366B1 (en) 2018-10-10

Similar Documents

Publication Publication Date Title
CN105209909B (zh) 与肾功能相关的生物标记及其使用方法
Loftfield et al. Comparison of collection methods for fecal samples for discovery metabolomics in epidemiologic studies
JP6763770B2 (ja) 自閉症スペクトラム障害のバイオマーカー
US20170343567A1 (en) Methods and systems for metabolite and/or lipid-based detection of colorectal cancer and/or adenomatous polyps
JP2015231392A (ja) 自閉症の代謝バイオマーカー
CN104204798A (zh) 膀胱癌的生物标志物和使用所述生物标志物的方法
BRPI0709374A2 (pt) técnica de obtenção de impressão digital de apolipoproteìna e métodos relacionados á mesma
Chen et al. Targeting amine-and phenol-containing metabolites in urine by dansylation isotope labeling and liquid chromatography mass spectrometry for evaluation of bladder cancer biomarkers
JP5522365B2 (ja) 代謝物の異常度の取得方法、代謝異常の判定方法、及びそのプログラム、並びに、代謝物の異常度の取得装置、及び代謝異常の判定に基づく診断プログラム
Sazonov et al. Metabolomics in search of noninvasive biomarkers for allograft rejection in pediatric kidney transplantation
Faber et al. Metabonomics in diabetes research
CN114758719A (zh) 一种结直肠癌预测系统及其应用
Miller et al. Pulmonary fibrosis diagnosis and disease progression detected via hair metabolome analysis
CN117877567A (zh) 用于烟雾病临床早期诊断的代谢标志物及其应用
CN114755422B (zh) 一种结直肠癌检测的生物标志物及其应用
TWI858977B (zh) 生物標記物組、為個體提供老化標記物水平表示的方法、用於提供對個體的生物年齡預測的方法及套組
CN101523219A (zh) 与磷脂沉积症有关的线粒体毒性的生物标记
CN121324513A (zh) 基于代谢组学的泛发性脓疱型银屑病诊断标志物及其应用
CN118566488B (zh) 抑郁症检测用试剂组合、制造方法、检测系统及其应用
US20230402131A1 (en) Biomarker and diagnosis system for colorectal cancer detection
CN116165385B (zh) 用于肝癌诊断的血清代谢标志物及其筛选方法和应用
HK1218331B (zh) 与肾功能相关的生物标记及其使用方法
Yu et al. Non-destructive identification of forensically relevant body fluid stains using a portable electronic nose: A pilot study
CN118294676A (zh) 基于关键标志物的抑郁症检测试剂、检测系统及其应用
EP4565883A1 (en) Metabolic vulnerability analyzed by nmr

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1218331

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant